Estimation of tumor proliferative activity according to expression of cell-cycle-related antigen and selection of fractionation schema in radiation therapy.

根据细胞周期相关抗原的表达和放射治疗中分割方案的选择来估计肿瘤增殖活性。

• 批准号: 08671025
• 负责人: NISHIMURA Yasumasa
• 金额: $ 1.6万
• 依托单位: KYOTO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08671025/
• 关键词: radiation therapy,; fractionation; proliferative activity; Q cell; cell-cycle-related antigen; immunohistochemical staining; antiangiogenic agent; 放射線治療; 免疫組織科学染色; 多分割照射; PCNA; Ki-67; 放射線分割照射; 細胞周期関連遺伝子

We have performed various basic and clinical studies on tumor proliferation and radiation therapy,1)To understand better the repopulation kinetics of tumor cells after radiotherapy (RT), we investigated changes in cell proliferative parameters after single-dose irradiation of murine tumors. As one of conclusions, recruitment of previously quiescent cells into the proliferative pool in the tumors was suggested to contribute to repopulation after RT.(ref.2)2)Combined effects of an antiangiogenic agent (TNP-470) with fractionated RT were investigated using a murine tumor. The tumor control probability decreased by administrating TPN-470 during fractionated RT in air. This unexpected result may be contributable to partial inhibition of reoxygenation by TNP-470, because no significant changes in TCD-50 under hypoxic conditions by TNP-470. (ref.6)3)The effects of overall treatment time (OTT) on local control of RT were evaluated to consider optimal OTT in RT.Local control rates and acute and … More late toxicities of esophageal cancer, glottic cancer, and uterine cervical cancer were analyzed. In the multivariate analysis, OTT was a significant prognostic factor for local control. In conclusion, OTT should be kept as short as Possible wiyhin the limits of tolerance of normal tissues and patients. (ref.4)4)The relationship of immunohistochemical indices of proliferating cell nuclear antigen (PCNA) and Ki-67 to local control and survival rates for patients with esophageal squamous cell carcinomas treated by definitive radiotherapy (RT) was investigated. Biopsy materials before RT were obtained from 65 patients with esophageal cancer. The PCNA LI was independent of known prognostic factors on local control for esophageal cancer. Patients with the PCNA LI of<50% or the Ki-67 LI of<45% showed significantly higher local recurrence rates than those with higher LIs (p<0.05). In conclusion, PCNA LI and Ki-67 LI were significantly correlated with local control probabilities in esophageal. squamous cell carcinomas treated by definitive RT.PCNA LI may be a useful parameter for selecting the fractionation scheme of esophageal cancers. Less

1)为了更好地了解肿瘤细胞在放疗后的再增殖动力学，我们观察了小鼠肿瘤单次照射后细胞增殖参数的变化。作为结论之一，先前静止的细胞重新聚集到肿瘤的增殖池中被认为有助于RT后的再生长。(参考文献2)用小鼠肿瘤研究了抗血管生成剂(TNP-470)和分次RT的联合作用。在空气中分次放疗期间给予TPN-470可降低肿瘤控制率。这一意想不到的结果可能与TNP-470部分抑制复氧有关，因为TNP-470在缺氧条件下TCD-50没有显著变化。(参考文献6)3)评估总体治疗时间对RT局部控制的影响，以考虑RT的最佳局部治疗时间。局部控制率、急性和…分析了食道癌、声门癌和宫颈癌的更多晚期毒性反应。在多因素分析中，OTT是局部控制的重要预后因素。总之，OTT应在正常组织和患者的耐受性范围内尽可能短。(参考文献4)探讨增殖细胞核抗原和Ki-67免疫组织化学指标与食管鳞癌根治性放疗患者局部控制率和生存率的关系。本文收集了65例食管癌患者放疗前的活检资料。PCNALI与已知的食管癌局部控制预后因素无关。PCNALI为50%或Ki-67LI为45%的患者的局部复发率显著高于LIS高者(p&lt；0.05)。结论：PCNALI和Ki-67LI与食管局控率显著相关。RT-PCNALI治疗鳞状细胞癌可作为选择食道癌分割方案的有用参数。较少

项目成果

Nishimura Y.,et.al.: "Optimal overall treatment time in fractionated radiotherapy for head and neck cancers,esophageal cancer,and uterine cervical cancer." J.Jpn.Soc.Ther.Radiol.Oncol.8. 303‐315 (1996)

Nishimura Y.,et.al.：“头颈癌、食道癌和宫颈癌分次放射治疗的最佳总体治疗时间。”J.Jpn.Soc.Ther.Radiol.Oncol.8。 1996）

Nishimura Y., et al: "Optimal overall treatment time in fractionated radiotherapy for head and neck cancere,esophageal cancer and uterine cervical cancer." J.Jpn.Soc.Ther.Radiol.Oncol.8. 303-315 (1996)

Nishimura Y.等人：“头颈癌、食道癌和宫颈癌分段放射治疗的最佳总体治疗时间。”

Shibamoto Y,Ohshio G,Hosotani R,Nishimura Y,Manabe T,Imamura M,Abe M.: "A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy." Br J Cancer. 76. 1474-1479 (1997)

Shibamoto Y、Ohshio G、Hosotani R、Nishimura Y、Manabe T、Imamura M、Abe M.：“缺氧细胞放射增敏剂 KU-2285 与术中放疗相结合的 I/II 期研究。”

Shibamoto Y., Nishimura Y., Tsutsui K., Sasai K., Takahashi M., Abe M.: "Cmparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma." Jpn.J.Clin Oncol. 27. 31-36 (1997)

Shibamoto Y.、Nishimura Y.、Ttsutsui K.、Sasai K.、Takahashi M.、Abe M.：“加速超分割放射治疗和常规放射治疗幕上恶性胶质瘤的比较。”

Shibamoto Y., Nishimura Y., 他: "A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy" Br.J.Cancer. 76. 1474-1479 (1997)

Shibamoto Y.、Nishimura Y. 等人：“低氧细胞放射增敏剂 KU-2285 与术中放疗联合的 I/II 期研究”Br.J.Cancer 76. 1474-1479 (1997)